Sana Biotechnology reported second quarter 2026 financial results, posting a net loss of $63.6 million ($0.22 per share) compared to $93.8 million in the prior year period. The company raised $93.3 million in net proceeds from equity financings through its at-the-market offering facility and a strategic collaboration with Mayo Clinic, which included a $25.0 million equity investment by Mayo Clinic. Cash position stood at $160.5 million as of June 30, 2026, providing an expected cash runway into mid-2027. The company highlighted progress toward initiating Phase 1/2 clinical trials for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, alongside the publication of long-term UP421 data in The New England Journal of Medicine. Sana Biotechnology is a biotechnology company focused on creating and delivering engineered cells as medicines.